Loyens & Loeff advised QPS Holdings LLC in respect of the acquisition of Xendo Drug Development B.V. (XDD) for an undisclosed consideration. XDD, a European contract research organisation (CRO), will be known as QPS Netherlands B.V. and become a wholly-owned subsidiary of QPS Holdings LLC. XDD has more than 100 employees. With the completion of this acquisition, QPS further expands its global range of linearly integrated resources and services.

The Loyens & Loeff team was led by Willem Bongaerts.